摘要
目的探讨鼻咽癌组织中DNA切除修复交叉互补基因1(ERCC1)的mRNA表达水平与Ⅱ期鼻咽癌顺铂同步放化疗疗效关系。方法 78例初诊经鼻咽肿物活检确诊为鼻咽部低分化鳞癌的Ⅱ期鼻咽癌患者,取患者化疗前肿瘤组织通过RT-PCR方法检测其ERCC1 mRNA表达水平,患者均接受顺铂同步放化疗。通过RECIST 1.1实体瘤疗效评定标准评定近期疗效,分析ERCC1 mRNA表达水平与近期疗效的关系。结果78例患者均可评价疗效,有效率为89.74%,疾病控制率为94.87%。Ⅱ期鼻咽癌组织中ERCC1 mRNA的中位数水平为1.119。化疗前Ⅱ期鼻咽癌组织中ERCC1 mRNA的表达水平与治疗后的近期疗效有显著相关性(P<0.05)。结论 ERCC1 mRNA表达水平对Ⅱ期鼻咽癌顺铂同步化疗疗效及预后有一定的预测价值。
Objective To investigate the relationship between the expression of excision repair cross-complementing gene 1（ ERCC1） mRNA of stage Ⅱ nasopharyngeal carcinoma and effect of cisplatin concurrent radiochemotherapy for nasopharyngeal carcinoma. Methods RT-PCR method was used to detect the expression of ERCC1 in78 patients with stage Ⅱ nasopharyngeal carcinoma before treatment,and all the 78 patients were treated with cisplatin concurrent radiochemotherapy. The short-term effect was evaluated by RECIST 1. 1 solid tumors evaluation criteria,and the relationship between the expression of ERCC1 mRNA and effect of cisplatin concurrent radiochemotherapy for stage Ⅱ nasopharyngeal carcinoma was analyzed. Results Of all the 78 patients,the effective rate was89. 74%,the disease control rate was 94. 87%. The median of ERCC1 mRNA expression levels was 1. 119. The expression of ERCC1 mRNA was positively related with effect of cisplatin concurrent radiochemotherapy for nasopharyngeal carcinoma. Conclusion The predictive value of expression of ERCC1 mRNA is clear for efficacy of cisplatin chemotherapy in the treatment of stage Ⅱ nasopharyngeal carcinoma.
出处
《肿瘤基础与临床》
2016年第5期373-376,共4页
journal of basic and clinical oncology
基金
广西自然科学基金面上项目(编号:2011GXNSFA018236)
柳州市重大项目(编号:2014J030404)
关键词
DNA切除修复交叉互补基因1
Ⅱ期鼻咽癌
顺铂
excision repair cross-complementing gene 1
stage Ⅱ nasopharyngeal carcinoma
cisplatin
